Benralizumab
- US DailyMed: Benralizumab
category
- AU: B1
administration
- R03DX10 (WHO)
- AU: S4 (Prescription only)
- CA: ℞-only / Schedule D[1]
- UK: POM (Prescription only)
- US: ℞-only
- EU: Rx-only[2]
- 1044511-01-4 N
- DB12023 Y
- none
- 71492GE1FX
- D09874 N
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma.[3][4]
Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[5][6] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma.[7] It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.[8]
Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.[9]
References
- ^ "Regulatory Decision Summary for Fasenra". 23 October 2014.
- ^ "Fasenra EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2020.
- ^ Statement on a Nonproprietary Name Archived 15 August 2016 at the Wayback Machine adopted by the USAN Council: Benralizumab
- ^ Catley MC (September 2010). "Asthma & COPD--IQPC's Second Conference". IDrugs. 13 (9): 601–4. PMID 20799138.
- ^ House DW (5 September 2016). "AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies". Seeking Alpha. Retrieved 7 September 2024.
- ^ Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. (June 2017). "Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma". The New England Journal of Medicine. 376 (25): 2448–2458. doi:10.1056/NEJMoa1703501. PMID 28530840.
{{cite journal}}
: CS1 maint: overridden setting (link) - ^ "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma" (Press release). AstraZeneca. 14 November 2017.
- ^ "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis". AstraZeneca (Press release). 28 August 2019. Retrieved 29 October 2019.
- ^ FDA Professional Drug Information
- v
- t
- e
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e